Superworth

GRI Bio revenue GRI

Sales by quarter and over the last twelve months, from 2020.

Last 12 months, to Mar 31, 2022
$0
Latest quarter, Q1 FY22
$0
Fiscal year 2021
$0
−100% on the year before

GRI Bio's revenue was $0 over the twelve months to Mar 31, 2022.

In its latest quarter, Q1 FY22, it was $0.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2021$0−100%
FY2020$100Kn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q1 FY22$0n/a$0
Q4 FY21$0n/a$0
Q3 FY21$0n/a$0
Q2 FY21$0n/a$0
Q1 FY21$0−100%$0
Q4 FY20$0n/a$100K
Q3 FY20$0n/an/a
Q2 FY20$0n/an/a
Q1 FY20$100Kn/an/a

Against its peers

Companies in Healthcare nearest GRI Bio's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
GRIGRI Bion/m
OXBROXBRIDGE RE HOLDINGS$2.8M+40% a year
EDUCEducational Development$20M−32% a year
GTIMGood Times Restaurants$135.1M−6% a year
MDRRMedalist Diversified$9.6M−1% a year
BCGBinah Capital$191.9M+8% a year
VIPVulcan Infrastructure & Power$50.9M−14% a year
MXCMexco Energy$6.7M−9% a year
CKXCKX Lands$693.4K−17% a year
MSGMMotorsport Games$14.5M+79% a year
ATCHAtlasClear$20.1M+85% a year
Peer median$17.3M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on GRI Bio

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.